Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical on MSN3d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...
See privacy policy. [LIMA, PERU] Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an ...
In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback